L. Rubinstein

发表

Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

D A Scudiero, K D Paull, D. Scudiero, 1989, Journal of the National Cancer Institute.

Morphometric and Colorimetrie Analyses of Human Tumor Cell Line Growth and Drug Sensitivity in Soft Agar Culture1

M. Boyd, L. Rubinstein, M. Alley, 2006 .

Morphometric and colorimetric analyses of human tumor cell line growth and drug sensitivity in soft agar culture.

M. Boyd, L. Rubinstein, M. Alley, 1991, Cancer research.

Data Display and Analysis Strategies for the NCI Disease-Oriented in Vitro Antitumor Drug Screen

Kenneth D. Paull, Michael R. Boyd, M. Boyd, 1992 .

Expanding access to early phase trials: the CATCH-UP.2020 experience

M. Mooney, S. Gore, L. Rubinstein, 2022, JNCI cancer spectrum.

Exploratory data analytic techniques to evaluate anticancer agents screened in a cell culture panel.

K. Paull, L. Hodes, L. Rubinstein, 1992, Journal of biopharmaceutical statistics.

TET2 and DNMT3A mutations and exceptional response to 4′-thio-2′-deoxycytidine in human solid tumor models

Dat Quoc Nguyen, J. Doroshow, Sherry X. Yang, 2021, Journal of Hematology & Oncology.

Statistical Review for Medical Journals, Guidelines for Authors

L. Rubinstein, 2005 .

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data

L. Rubinstein, L. Rubinstein, J. Zujewski, 2017, npj Breast Cancer.

State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report.

Weidong Lu, Dan Xi, Mark Levine, 2017, Journal of the National Cancer Institute. Monographs.

Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.

L V Rubinstein, D A Scudiero, K D Paull, 1990, Journal of the National Cancer Institute.

Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.

L V Rubinstein, D A Scudiero, A D Koutsoukos, 1992, Cancer research.

Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.

W G Alvord, L V Rubinstein, K D Paull, 1996, Cancer research.

Neural computing in cancer drug development: predicting mechanism of action.

J N Weinstein, K W Kohn, M R Grever, 1992, Science.

Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS

M. Grever, T. Myers, J. Weinstein, 1994, Stem cells.

Discrimination techniques applied to the NCI in vitro anti-tumour drug screen: predicting biochemical mechanism of action.

D Faraggi, J N Weinstein, K W Kohn, 1994, Statistics in medicine.